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CC BY-NC-ND license (http://creativeAbstract The purpose of the study was to compare the results of panretinal photocoagulation
(PRP) using the pattern scan laser (PASCAL) in a single setting versus multiple sessions of stan-
dard YAG laser in patients with proliferative diabetic retinopathy. Charts of 35 eyes that were
treated with the PASCAL and an equal number of eyes that were treated with conventional laser
were retrospectively reviewed. The whole PRP treatment was performed in one session in the
PASCAL group, whereas all the patients in the conventional-laser group completed the entire
PRP treatment in two or three sessions. Persistence and/or recurrence of neovascularization,
complications encountered, total number of laser spots, and mean power used were compared.
Patients treated with the PASCAL received significantly higher number of laser spots than those
treated with conventional laser (2885 vs. 1642, p < 0.001). The PASCAL and conventional-laser
systems required an average power of 650 mW and 330 mW, respectively (p < 0.001). Patients
treated with the PASCAL showed similar rates of treatment failure within 12 months of follow-
up compared with patients treated with conventional laser (14% vs. 11%, p > 0.05). In the
PASCAL group, vitreous hemorrhage, neovascular glaucoma, retinal hemorrhage, and choroidal
detachment were reported in two, two, one, and two patients, respectively, whereas only one
each vitreous hemorrhage and neovascular glaucoma were encountered in the conventional-
laser group. Our study reports that single-session PRP with the PASCAL has similar efficacy
compared with conventional laser, and has a favorable side-effect profile.
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Panretinal photocoagulation (PRP) gained acceptance as
the standard treatment for high-risk proliferative diabetic
retinopathy (PDR) after the landmark report of the Diabetic
Retinopathy Study, which stated that PRP for high-risk PDR
decreased the risk of severe vision loss by more than 50%
[1]. Later, the Early Treatment Diabetic Retinopathy Study
[2] confirmed the effectiveness, indications, and guidelines
of photocoagulation in PDR. Conventional-laser delivery
systems create only one laser spot on a single foot-switch
depression with spot sizes ranging from 100 mm to
500 mm, and pulse durations from 100 ms to 200 ms. The
duration of treatment needed to perform the total PRP
treatment relies on characteristics of the system and the
physician’s ability. Since each spot is delivered one by one
in standard laser, the procedure takes much time and is
annoying, and often causes patient disturbance. For this
reason, clinicians generally perform PRP in more than one
session. The other reason for performing PRP in more than
one session is the inflammation after treatment.
Blumenkranz et al [3] reasoned that greater precision
and safety in retinal photocoagulation might be achieved by
a new instrument, and based upon this idea, they have
generated a new frequency-doubled 532-nm wavelength
Nd:YAG laser, which is able to deliver multiple spots up to 56
shoots following the activation of the foot pedal. The
commercially available version of this laser is named as
pattern scan laser (PASCAL; OptiMedica Corp., Santa Clara,
CA, USA), which the U.S. Food and Drug Administration gave
clearance in 2005. This new instrument is semiautomatic,
which means that the physician has control over the treat-
ment at all times. Laser delivery can be activated or inter-
rupted at any time by pressing or releasing the foot pedal.
The fully integrated, slit-lamp-mounted retinal photo-
coagulator uses a microprocessor-driven scanner, which
creates various patterns that are visible on the screen of a
computer. The physician can choose one of the several
prearranged patterns consisting of lines, squares, and cir-
cular arcs. The range of pulse durations is from 10 ms to
30 ms. These new characteristics of the PASCAL have been
anticipated to shorten the PRP procedure. Reduced thermal
diffusion of the laser energy into the choroid, which has a
dense sensory nerve plexus due to the shorter pulse duration
of the PASCAL system compared to conventional-laser sys-
tems, is assumed to cause lower pain levels. Enlargement of
laser burns is also reduced due to decreased pulse duration,
which has consequences of lower collateral retinal damage
and better preservation of retinal sensitivity [3,4].
In this study, we aimed to compare the results of PRP
using the PASCAL in a single setting with multiple sessions of
a conventional, single-spot, slit-lamp delivery, 532-nm
solid-state Nd:YAG laser (GYC 1500; Nidek Co., Ltd.,
Aichi, Japan) in patients with newly diagnosed high-risk
PDR. In addition, we evaluated the probable advantages
and risks of a single-session PASCAL system.
Methods
We performed a retrospective review of consecutive pa-
tients in our clinic, which were diagnosed with high-riskPDR. This study was performed between September 2012
and June 2013, and patients were followed up at least
12 months. A total of 35 eyes of 35 patients were identified
from the patients’ medical records, which had consecutive
PRP treatment utilizing the PASCAL. We subsequently
determined the same number of eyes of consecutive pa-
tients with the same inclusion criteria, which had PRP
treatment using a conventional laser. After purchase of the
PASCAL, we preferred this new device as the first choice of
treatment for retinal photocoagulation in our clinic. The
study followed the tenets of the Declaration of Helsinki,
and informed consent was obtained from all patients.
The inclusion criteria were (1) age at least 18 years or
more; (2) newly diagnosed high-risk PDR; (3) no previous
PRP; (4) if vitreous hemorrhage was present, then media
clarity sufficient to perform a complete laser; (5) follow-up
of at least 12 months; and (6) best-corrected visual acuity
of 6/60 or better. High-risk PDR was defined as neo-
vascularization of the disk greater than one-third disk area,
neovascularization of the disk associated with vitreous
hemorrhage or preretinal hemorrhage, or neo-
vascularization elsewhere at least one-half disk area in size
and associated with vitreous hemorrhage or preretinal
hemorrhage.
We dilated the pupils with 1% tropicamide and 2.5%
phenylephrine-hydrochloride drops, and used 0.5%
proparacaine-hydrochloride drops as topical anesthetic
before the procedure. One experienced surgeon (G.S.) in
both lasers performed all the laser procedures. A Mainster
165 contact lens (Ocular 148 Instruments Inc., Bellevue, WA,
USA) was used for all eyes. The PASCAL PRP parameters were
defined as 200-mm spot size, 20e30 ms pulse duration, and
power was adjusted until a grayewhite lesion was observed
starting from 200 mW. The whole PRP treatment was per-
formed in one session. With the PASCAL, we used a 5  5,
4  4, or 3  3 box grid based on the surgeon’s preference.
The following settings were used for conventional laser:
200-mm spot size, 200-ms pulse duration, and power
increased from 200 mW until a grayewhite lesion was
attained. Burns were placed one burn width apart. All of
the patients completed the entire PRP treatment in two or
three sessions.
Persistence of neovascularization following treatment or
recurrence of neovascularization following initial regres-
sion was the outcome measure. “Persistence” was defined
as failure to show significant regression of neo-
vascularization at 3 months or more after the PRP treat-
ment had been completed. “Recurrence” of
neovascularization was defined as neovascularization
repeating after initial regression at any time during the
follow-up period of 12 or more months. “Treatment fail-
ures” were patients who had shown either persistence or
recurrence of neovascularization over the follow-up period.
On the other hand, all patients in the successfully treated
group showed complete regression of neovascularization
after 3 months following completion of the PRP treatment,
and showed no recurrence of the neovascularization during
the follow-up period. Regression and persistence or recur-
rence of neovascularization were noted clinically and
documented with color fundus photographs.
In addition, incidence of vitreous hemorrhage after PRP
treatment, neovascularization of the iris, neovascular
24 R.G. Seymenoglu et al.glaucoma (NVG), and complications of PRP were noted. All
patients who had recurrence or persistence of neo-
vascularization were given additional laser treatment.
Data are expressed as mean values (standard deviation)
or number of patients (percent of patients affected). The
Chi-square test was used to compare the outcome measures
for PASCAL-treated versus conventional-laser-treated pa-
tients. After normal distribution of data was confirmed with
the KolmogoroveSmirnov test, other variables, such as
number of laser spots, laser power, glycated hemoglobin,
and age, were evaluated by the independent-sample t test.
The significance was set at p < 0.05.Results
Seventy patients participated in the study; there were 35
patients in the conventional-laser group and 35 patients in
the PASCAL group. At baseline, there was no significant
difference between the groups (p > 0.05, for all) in terms
of age, sex, most recent glycated hemoglobin, or diagnosis,
as shown in Table 1.
We used a mean power of 650 mW in the PASCAL group
(range: 250e1500 mW) and a mean power of 330 mW in the
conventional group (range: 200e600 mW). The mean
powers used in two different lasers differed significantly.
The PASCAL group required much power because the
duration used in PASCAL was 20e30 ms. In order to perform
a complete PRP procedure, the PASCAL required a mean
number of 2885 laser spots (range: 2100e3951 spots),
whereas the conventional laser required a mean number of
1642 spots (range: 1364e1948 spots).
Fourteen percent (5 of 35) of eyes that were treated
with PASCAL had treatment failure, which was certified by
persistence or recurrence of neovascularization after
12 months of follow-up, compared with 11% (4 of 35) ofTable 1 Baseline comparison between the study groups.
Variables PASCAL Conventional
laser
p
Age, mean  SD (y) 61.90  7.98 64.22  5.85 0.31
Sex, n (%)
Female 16 (45.7) 17 (48.6) 0.99
Male 19 (54.3) 18 (51.4)
HbA1c, mean  SD (%) 8.9  0.52 8.6  0.34 0.75
Duration of disease,
mean  SD (y)
14.1  6.8 17.0  8.2 0.40
Diagnosis, n 4/31 2/33 0.77
Type 1/type 2
LOCS III
NO 2.93 2.89 > 0.05
NC 2.66 2.5 > 0.05
C 1.38 1.36 > 0.05
P 3.12 2.99 > 0.05
C Z cortical cataract; HbA1c Z glycated hemoglobin; LOCS
III Z Lens Opacities Classification System III; n Z number;
NC Z nuclear color; NO Z nuclear opalescence; P Z posterior
subcapsular cataract; PASCAL Z pattern scan laser;
SD Z standard deviation.those eyes that received conventional PRP (p > 0.05).
Three out of 35 eyes (8.6%) that received treatment by the
PASCAL showed persistence of neovascularization following
treatment, compared with the same number of eyes
treated with conventional laser. The neovascularization in
two of the 32 eyes (5.7%) that initially regressed after PRP
treatment by the PASCAL showed recurrence, compared to
one of 32 (2.9%) eyes that were given PRP treatment with
the conventional laser, as shown in Table 2 (p > 0.05).
In addition, two (vs. one) patients developed vitreous
hemorrhage in the PASCAL-treated group during the follow-
up period, as shown in Table 3. Two patients experienced
NVG in the PASCAL-treated group, whereas one patient
experienced NVG in the conventional-laser-treated group.
In the PASCAL group, one case of choroidal rupture and
retinal hemorrhage secondary to microexplosion and two
cases of choroidal detachment were reported. However,
these cases self-resolved over time without any significant
intervention. No complications except for one vitreous
hemorrhage and NVG were encountered in the
conventional-laser group.
Discussion
PRP is yet well accepted as the gold standard, despite
newer pharmacological agents are presented to the market
in the treatment of high-risk PDR. The exact mechanism of
PRP treatment that causes regression of neovascularization
still continues to be unknown. It is mainly proposed that the
mechanism was associated with the devastation of photo-
receptor cells, which have an abundant supply of mito-
chondria and consume a high amount of oxygen. These cells
are in favor of glial scars, which have a lower amount of
mitochondria. Therefore, the oxygen need of the outer
retina decreases, and its diffusion to the inner retinal
layers from the choroid becomes easier. Hypoxia in the
inner retinal layers is alleviated by elimination of a frag-
ment of the hypoxic retina and the vasoproliferative fac-
tors. Thus, neovascularization is decreased or interrupted
[5].
On the other hand, the intended therapeutic devasta-
tion of the retina by laser photocoagulation leads to the
inevitable devastation of healthy retina lying next to the
photocoagulated area [6e8]. It has been reported thatTable 2 Comparison of clinical outcomes between the
pattern scan laser and conventional laser.
Variables PASCAL
(n Z 35)
Conventional
laser (n Z 35)
p
Mean power (mW) 650 330 < 0.001
Range 250e1500 200e600
Mean number of spots 2885 1642 < 0.001
Range 2100e3951 1364e1948
Treatment failure,
n (%)
5 (14) 4 (11) > 0.05
Persistence, n (%) 3 (8.6) 3 (8.6) > 0.05
Recurrence, n (%) 2 (5.7) 1 (2.9) > 0.05
n Z number; PASCAL Z pattern scan laser.
Table 3 Comparison of complications between the
pattern scan laser and conventional laser.
Variables PASCAL
(n Z 35)
Conventional
laser (n Z 35)
p
Vitreous hemorrhage 2 1 > 0.05
Neovascular glaucoma 2 1 > 0.05
Retinal hemorrhage 1 0 > 0.05
Choroidal detachment 2 0 > 0.05
n Z number; PASCAL Z pattern scan laser.
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cant deficiency in the function of outer retinal layers within
2 months [9]. The width and axial extent of the retinal le-
sions are smaller and less dependent on variations in laser
power at shorter pulse durations than at longer durations.
Lateral dissipation may account for spot-size enlargement
over time [10]. This is potentially harmful, as spot coales-
cence, when not spaced adequately, may give rise to un-
fortunate scotomas. Vertical dissipation may result in full-
thickness retinal scarring [11], with choroidal involve-
ment, resulting in greater pain [4]. Pulse durations of
approximately 20 ms have been proposed to represent an
optimal compromise between the favorable impact of
speed, higher spatial localization, and reduced collateral
damage [11].
The PASCAL is a faster laser and presents greater facility
than the conventional lasers in PRP treatment for high-risk
PDR patients [12]. In the present study, when both lasers
were utilized with the same size of laser spots in similar
patients, the PASCAL treatment had similar efficacy
compared with the conventional-laser systems. Both
treatments, including the two laser systems, induced
regression and avoided the recurrence of neo-
vascularization in patients with high-risk PDR. However, we
required greater power with the PASCAL system than the
conventional-laser system (650 mW vs. 330 mW) to achieve
the same intensity burns. Furthermore, the average num-
ber of laser spots required for PRP treatment in the PASCAL
system was much more than that in the conventional-laser
system (2885 vs. 1642).
Chappelow et al [12] reported that the PASCAL was less
effective than the traditional argon laser in both obtaining
regression and avoiding recurrence of neovascularization in
patients with high-risk PDR, when both lasers were utilized
with similar number and size of laser spots in similar pa-
tients. As they stated, they used similar number of laser
spots in both laser systems. Since a logarithmic increase in
retinal lesion size as a function of increasing pulse duration
was reported [11], we may postulate that the total area of
PRP scars in the argon-treated patient may be greater than
that in the PASCAL-treated patient. There was an increased
rate of neovascularization recurrence in the PASCAL-
treated patients. The authors concluded that, if an equal
number of laser spots were administered, then the total
burn area created by the PASCAL would be smaller than the
argon laser, and this would cause a significant decrease in
efficacy. In the present study, we performed a significantly
higher number of laser spots in the PASCAL system than that
in the conventional-laser system. Thus, we obtainedproportionate efficacy with the PASCAL compared with the
conventional Nd:YAG laser.
The Diabetic Retinopathy Study [1] and the Early
Treatment Diabetic Retinopathy Study [2] had suggested
that more than 900 spots should not be applied in a single
session while carrying out PRP, due to complications of
laser photocoagulation. On the other hand, it was pointed
out that the consequences of a single-session therapy are
not harmful in the long term [13]. After all, single-session
PRP is not often performed due to long duration of laser
application and the disturbance associated with it. Some-
times, pain that the patients may complain can prevent
conventional laser to be performed in a single session. The
cause for pain can be multifactorial, including sex differ-
ence and anxiety levels. The pain after the PASCAL is re-
ported to be significantly less as compared to the pain after
the conventional laser, which makes the PASCAL possible to
be performed in a single session. The decreased pain in the
course of the laser therapy is considered to be due to the
decreased thermal diffusion into the choroid, which is rich
in sensory nerves [14e16].
The retrospective design of our study presents some
limitations. The patient number was too small to identify a
difference in occasional events, such as complications after
laser treatment. The study was not powered enough to
reveal a significant difference in the incidence of compli-
cations, such as vitreous hemorrhage. For this purpose,
more number of patients should have been included in the
study.
Two cases in the PASCAL group developed choroidal
detachment, while none of the cases in the conventional-
laser group did so. Some studies reported that choroidal
detachment or angle-closure glaucoma developed more
frequently in a single session, but these complications were
temporary with no detrimental effect in the long term
[13,17e20]. In the present study, two cases of choroidal
detachments were self-resolving, and single-session PRP
seemed to be a feasible option. However, care must be
taken with spot counts going over 3000, because two cases
of choroidal detachments in the PASCAL group had both
more than 3000 laser spots in a single session.
In the PASCAL group, only one case each of retinal
hemorrhage and choroidal rupture were reported. This is a
rare complication, and care must be taken particularly with
high-power settings when moving to the peripheric retina.
The exact focusing of the laser beam throughout the entire
length of the large laser patterns (e.g., arc pattern) may be
inhibited by the spherical curvature of the globe, and this
may eventuate in variable laser burns, particularly in the
far periphery. This can be alleviated to some extent by
diminishing the laser-pattern size and/or length. Also, the
laser power should be frequently titrated during the pro-
cedure especially in the peripheral retinal regions. How-
ever, with regard to our experience, we were not able to
get equal burn density for all the spots in the laser pattern
in many cases. Thus, care must be taken when performing
laser treatment with larger arrays, and single-spot treat-
ment may be undertaken when shooting in the periphery.
In conclusion, our study reports that, in the setting of
high-risk PDR, single-session PRP with PASCAL has similar
efficacy compared with conventional laser at controlling a
proliferative disease. It is a promising procedure with
26 R.G. Seymenoglu et al.favorable safety profile. The efficacy and complications of
PASCAL should be further demonstrated by performing
long-term clinical trials with larger sample size.
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